Mr. Cornelissen has primary responsibility for financial reporting, budgeting, cash-flow management, investments, information technology and facilities. He has served as Xencor’s chief financial officer since 2024. Before Xencor, Mr. Cornelissen was vice president, corporate finance at Seagen Inc., where he built and scaled the corporate finance organization to support tremendous revenue growth and dealmaking activity, including the company’s $43 billion acquisition by Pfizer in 2023. Before Seagen, while at the Bill & Melinda Gates Foundation, he served as vice president, finance for the END Fund and as finance lead for malaria and neglected tropical disease initiatives. Earlier in his career, Mr. Cornelissen led multiple finance teams at DSM Nutritional Products, a former division of Roche. He began his career in life sciences and health within global financial planning and analysis at Novartis. Mr. Cornelissen received his M.Sc. in Business Administration from the Rotterdam School of Management at Erasmus University.